From: Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
Pre | 1 month | 3 months | 6 months | 12 months | |
---|---|---|---|---|---|
Body weight (kg) | 66.7 ± 3.6 | – | – | 64.7 ± 3.5* | 63.8 ± 3.5*# |
Body mass index | 25.6 ± 1.1 | – | – | 24.7 ± 1.0* | 24.3 ± 1.0* |
Metabolic syndrome | 19 (54%) | – | – | 10 (29%) | 8 (23%)* |
Hemoglobin (g/dL) | 12.5 ± 0.4 | 12.6 ± 0.4 | 12.7 ± 0.4 | 12.8 ± 0.4 | 13.3 ± 0.4*$+ |
Hematocrit (%) | 38.0 ± 1.1 | 38.4 ± 1.2 | 38.3 ± 1.2 | 38.6 ± 1.2 | 40.7 ± 1.2*$+# |
HbA1c (%) | 6.61 ± 0.20 | 6.51 ± 0.21* | 6.52 ± 0.19 | 6.31 ± 0.19*$+ | 6.29 ± 0.19*$+ |
Insulin (μlU/mL) | 13.8 ± 3.2 | – | 18.3 ± 5.4 | 12.9 ± 2.5 | 13.8 ± 3.2 |
CPR (ng/mL) | 4.21 ± 0.35 | – | 4.36 ± 0.48 | 4.00 ± 0.39 | 3.47 ± 0.29+ |
Blood urea nitrogen (mg/dL) | 22.0 ± 1.5 | 22.2 ± 1.5 | 22.5 ± 1.3 | 22.0 ± 1.4 | 20.8 ± 1.2 |
Total cholesterol (mg/dL) | 147.4 ± 6.1 | 148.0 ± 6.2 | 147.4 ± 5.9 | 145.3 ± 5.8 | 143.1 ± 5.3 |
LDL (mg/dL) | 82.4 ± 4.8 | 82.5 ± 4.1 | 82.4 ± 4.0 | 79.5 ± 4.1 | 70.4 ± 3.9*$+# |
HDL (mg/dL) | 52.6 ± 2.5 | 54.2 ± 2.5* | 54.4 ± 2.4* | 55.5 ± 2.4* | 59.2 ± 3.0*$+# |
nonHDL (mg/dL) | 96.9 ± 4.6 | 95.8 ± 4.6 | 95.0 ± 4.1 | 91.9 ± 4.1 | 86.1 ± 3.5*$+ |
Triglyceride (mg/dL) | 159.2 ± 19.0 | 122.5 ± 11.5* | 111.7 ± 10.0* | 108.2 ± 11.4* | 107.7 ± 10.2*$ |
RLP-cho (mg/dL) | 5.89 ± 0.94 | – | 4.56 ± 0.58* | 4.48 ± 0.71* | 3.69 ± 0.62*+# |
EPA/AA | 0.52 ± 0.07 | – | 0.53 ± 0.07 | 0.55 ± 0.06 | 0.57 ± 0.06 |
hs-CRP (hs-CRP) | 0.39 ± 0.07 | 0.27 ± 0.06 | 0.20 ± 0.05* | 0.20 ± 0.04* | 0.21 ± 0.04* |
Renin (pg/mL) | 10.3 ± 3.9 | – | 29.6 ± 8.5* | 44.4 ± 10.7* | 50.7 ± 16.6* |
Angiotensin-II (pg/mL) | 30.0 ± 5.8 | – | 29.1 ± 5.2 | 20.2 ± 3.3*+ | 23.1 ± 5.7 |
Aldosterone (pg/mL) | 219.6 ± 30.3 | – | 177.9 ± 24.8* | 171.3 ± 21.9* | 169.2 ± 24.2* |
Urine sugar | 0.46 ± 0.19 | 3.63 ± 0.12 | 3.57 ± 0.12 | 3.46 ± 0.12 | 3.46 ± 0.12 |
Urine ketone | 0 | 0.03 ± 0.03 | 0 | 0 | 0.06 ± 0.04 |